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Preventing Sudden Cardiac Death in Young Athletes 
Preface 
This literature review will serve as a summary of research that is pertinent to the study of sudden 
cardiac arrest (SCA) and sudden cardiac death (SCD) in young athletes at the high school, 
collegiate, and early professional level. For the purpose of this paper, a young athlete is considered 
to be an individual under the age of 30 that participates in regular, intense, and organized training 
with the purpose of performing well in competition (Casa & Stearns, 2017).  It will outline the 
prevalence, various causes of SCA and SCD, prevention measures, pre-participation screenings, 
as well as distinguish the difference between SCD and SCA from a myocardial infarction. This 
review will also include case studies that were provided through interview and published articles.  
Physiological changes to an athlete’s heart 
As an athlete becomes more conditioned, physiologic changes occur in the heart. These changes 
depend on the type and amount of exercise performed and in order to acquire these adaptations, 
physical activity must be regular and intense (Whyte, Loosemore, & Williams, 2016). These 
changes are typically minimal, non-pathologic and they allow an athlete to maximize cardiac 
output during exercise (Whyte et al, 2016). Cardiac output is the product of heart rate and stroke 
volume. During exercise, the cardiac output increases because of the increase in oxygen the 
muscles need to continue to perform (Whyte et al, 2016). This increase in cardiac output is 
completed through an increase of both heart rate and stroke volume, with heart rate being the 
main factor (Whyte et al, 2016). As conditioning continues, hypertrophy of the left ventricle 
occurs meaning there is an increase in ventricle size, heart wall thickness, and diastolic filling 
(Whyte et al, 2016). These adaptations all increase an individual’s stroke volume. This increase 
in stroke volume increases cardiac output at rest and during exercise. Furthermore, due to this 
increase in stroke volume, a lower resting heart rate is observed in highly trained athlete’s 
(Whyte et al, 2016).  
 
Figure 1: Eccentric and concentric cardiac hypertrophy induced by exercise training: microRNAs 
and molecular determinants 
 
 
The difference in hemodynamic needs of different types of conditioning determines the type of 
cardiac modeling that will occur (Whyte et al, 2016). There are 2 main types of adaptation of the 
left ventricle; concentric and eccentric left ventricular hypertrophy (Fernandes, Soci, & Oliveira, 
2011). These changes are shown in Figure 1 from the Brazilian Journal of Medical and Biological 
Research in an article discussion eccentric and concentric cardiac hypertrophy induced by exercise 
(Fernandes et al, 2011). Concentric is characterized by an increase in left ventricular wall thickness 
and little to no amount of chamber dilation. The increase in wall thickness is non-pathologic and 
is caused by a pressure overload often seen in heavily resistance trained athletes (Fernandes et al, 
2011). Eccentric left ventricle hypertrophy is characterized by chamber dilation and little to no 
increase in ventricular wall thickness. This hypertrophy is also non-pathologic and is a result of 
volume overload (Fernandes et al, 2011). Sports that require athletes to be highly trained in both 
aerobic and resistance activities may see an overlap in hypertrophies, showing increased wall 
thickness and an increase in the left ventricle chamber size (Whyte et al, 2016). 
Sudden cardiac arrest and sudden cardiac death 
Sudden cardiac death (SCD) is defined as the sudden death of an individual due to cardiac-related 
causes within an hour of symptom onset (Katritsis, Gersh, & Camm, 2016). Sudden cardiac arrest 
(SCA) is when these cardiac-related issues cause a decrease and stopping of heart function but 
does not result in death (Katritsis et al, 2016; Drezner, Peterson, Seibert, Thomas, Lopez-
Anderson, Suchsland, & Kucera, 2018). This differs from a heart attack in that a heart attack is a 
blockage in an artery that leads to a decrease in blood flow to heart muscle (Whyte et al, 2016). 
There are a variety of causes associated with SCA and SCD in young athletes that include 
structural, electrical, and inherited cardiac abnormalities (Oliva, Grassi, Campuazno, Brion, Arena, 
Partemi, & Brugada, 2016). Most of these causes have no symptoms or warning signs and often 
SCA is the first sign of any cardiovascular disorder (Drezner et al, 2018; Maron, Haas, Murphy, 
Ahluwalia, & Rutten-Ramis, 2014). It is hard to record SCD in young athletes because there is no 
mandatory reporting of SCD in athletes across all levels of athletics from high school to 
professional and there is a struggle in defining what characterizes a competitive athlete (Casa & 
Stearns, 2017; Luna, 2000). In athletes, the hemodynamic demand of vigorous activity triggers 
arrhythmias in hearts with underlying diseases (Oliva et al, 2016; Casa & Stearns, 2017). Among 
the common causes of SCA and SCD in young athletes, some of the most prevalent are 
hypertrophic cardiomyopathy (HCM), commotio cordis, myocarditis, aortic rupture in Marfan 
syndrome, and arrhythmogenic right ventricular cardiomyopathy (ARVC) (Maron et al, 2014). 
Because SCA and SCD are caused by an unknown underlying cardiovascular disorder, detection 
and prevention are extremely important. Detection of an underlying abnormality could be the 
difference between a young athlete living and dying.  
Pathophysiology 
There are many causes of SCD in young athletes that ranges from electrical to structural but 
ventricular fibrillation (VF) appears in approximately 40% of cardiac arrests that take place outside 
of a hospital (Casa & Stearns, 2017).  When initial cardiac rhythm is measured, the rate of VF in 
athletes that suffer from SCA is higher than 40% (Casa & Stearns, 2017).  VF is a shockable 
rhythm and the use of an automated external defibrillator (AED) is successful in correcting it if 
used correctly and in a timely fashion (Casa & Stearns, 2017). Some of the top causes of SCA and 
SCD are listed and described in Table 1 but these are not all the causes and in some cases a 
diagnosis of SCA or SCD of idiopathic origin is given. This table is from the United States National 
Registry (Maron et al, 2016). 
 
 
 
Table 1: Demographics of Sudden Cardiac Death Causes in the United States 
 
 
Hypertrophic cardiomyopathy 
In the United States, the most common cause of SCD is HCM (Thomas, 1996). The reported 
number of SCDs that occur due to HCM varies due to the lack of a mandatory reporting protocol. 
Studies have found it to account for anywhere from one third to one half of all SCD occurrences 
(Casa & Stearns, 2017; Thomas, 1996). HCM is a condition in which there is hypertrophy of the 
left ventricle up to 16 mm in thickness or more (Casa & Stearns, 2017; Sheffle & Bowden, 2014). 
Normal left ventricle wall thickness is 12 mm or less and the ventricle is considered borderline if 
it falls between 13mm and 15 mm (Casa & Stearns, 2017). HCM impairs diastolic function of the 
ventricles, causes ventricles to become noncompliant, and leads to disorder of cardiac myocytes 
(Sheffle & Bowden, 2014). Contrary to concentric left ventricular hypertrophy, the enlarged 
ventricle wall can impair diastolic filling of the ventricle as well as impede blood flow out of the 
heart through the aortic semilunar valve in HCM (Casa & Stearns, 2017). HCM is inherited and 
an autosomal dominant abnormality that varies in expression. It occurs in about 1 out of every 500 
adults and is usually asymptomatic (Patel & Elliot, 2012). Symptoms may present themselves as 
syncope, ventricular fibrillation, chest pain, as well as mimic symptoms of other CVDs (Patel & 
Elliot, 2012). Although this abnormality accounts for such a high number of deaths, it is often not 
diagnosed in current pre-participation screening protocols (Patel & Elliot, 2012).  
 
Figure 2: ECG of patient with HCM from Duke Heart Center 
 
Athletes with HCM will have abnormal ECG results in 95% of cases (Casa & Stearns, 2017). 
HCM is hard to diagnose without an echocardiogram because on an ECG, characteristics of HCM 
and the physiologic change in an athlete’s heart look similar (Corrado & Zorzi, 2018). Figure 2 
shows an example of an ECG of a patient with HCM from the Duke Heart Center released in 2016 
(Heart, 2016). For example, concentric changes to the heart as a result of resistance training cause 
the increase in thickness in the heart wall. HCM is also an increase in the thickness of the heart 
wall, although, it is pathologic and impedes on blood flow throughout the heart. Nevertheless, 
these increases in thickness, though different, cause similar outcomes on an ECG (Casa & Stearns, 
2017). 4 to 6 weeks of deconditioning may be used to distinguish between HCM and athlete’s 
heart when using an ECG but this deconditioning period may be detrimental to performance in a 
highly competitive athlete (Casa & Stearns, 2017). 
Commotio cordis 
Commotio cordis is one of the few causes of SCD and SCA that cannot be predicted. Commotio 
cordis is an arrhythmia or full interruption of heart rhythm that is a result of an impact to the chest 
area over the heart (Davey, Quintana, & Upadhyay, 2018).  This impact often leads to VF which 
is lethal if not treated (Davey, Quintana, & Upadhyay, 2018). Commotio cordis is the second 
leading cause of SCD in young athletes and is unpredictable (Maron, 2012; Davey, Quintana, & 
Upadhyay, 2018). It can happen in a variety of sports including limited-contact sports by accident 
(Davey, Quintana, & Upadhyay, 2018).  
Myocarditis 
Myocarditis is characterized by inflammation of the myocardium (Casa & Stearns, 2017). It affects 
the heart muscle and electrical system leading to arrhythmias that cause SCA or SCD (Casa & 
Stearns, 2017; Myocarditis). Myocarditis is often caused by a viral infection but can also be the 
result of a poor reaction with a drug (Myocarditis). Myocarditis can be diagnosed using ECG, a 
chest X-ray, MRI scans, and an echocardiogram among other tests, but it is also typically 
accompanied by signs and symptoms such as chest pains and shortness of breath that act as red 
flags (Myocarditis). 
Marfan syndrome 
The physical examination looks for physical signs of Marfan syndrome which most commonly 
refers to long limbs (Thomas, 1996). In most individuals, a person’s height is greater than their 
wingspan but one of the most common signs of Marfan syndrome is the wingspan length exceeding 
the height of the individual (Thomas, 1996). Marfan syndrome is commonly associated with aortic 
dilation, aortic dysfunction, and an increased risk of aortic dissection (Thomas, 1996). Early 
detection of Marfan’s syndrome is important because a ruptured aorta due to Marfan’s accounts 
for 3.1% of all SCDs (Myerson, Sanchez-Ross, & Sherrid, 2012).  
Arrhythmogenic right ventricular cardiomyopathy 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an abnormality in the right 
ventricular myocardium (ARVC). This abnormality causes the breakdown of the heart muscle 
which increases the chance of having a lethal arrhythmia (ARVC). Some of the symptoms 
associated with ARVC are light-headedness, fainting, and a feeling of pounding in the chest but 
these symptoms are often not present in the early stages (ARVC). ARVC can be caused by many 
different gene mutations and seems to be genetically linked.  ARVC can be diagnosed using an 
ECG (Arrhythmogenic).  
Athletic fatalities 
Athletic fatalities are split into 2 categories; direct and indirect (Casa & Stearns, 2017). Direct 
refers to a death resulting directly participating in skills and drills associated with the sport (Casa 
& Stearns, 2017). Indirect refers to a systemic failure that occurs as a result of the exertion from 
participation in the sport (Casa & Stearns, 2017). SCD falls into the indirect category because it is 
a failure of the cardiovascular system to perform due to the physical requirements of participating 
in the sport.   
Prevalence 
SCD is the leading cause of exercise-induced death for young, competitive athletes, accounting 
for approximately 75% of all deaths (Drezner et al, 2018). It is hard to know the exact frequency 
of SCD in the young athlete population because of there are no regulations on reporting and it 
isn’t necessary to report a SCD occurrence at all (Drezner et al, 2018). Because the frequency of 
SCD in young athletes is anywhere from 1:9000 to 1:300000 depending on the study, there is a 
need for a mandatory reporting system to be in place in the United States (Casa & Stearns, 
2017). A reporting system, along with a universal definition of the term athlete in this context, 
would acknowledge the definite prevalence of SCD across all levels of competitive sport, from 
high school to professional. This information would assist in assessing the current pre-
participation screening and develop additions to these screening to, hopefully, decrease the 
frequency of SCA/D in young competitive athletes. The current definition of a competitive 
young athletes is an individual under 30 that competes in an organized team or individual sport 
that strives for excellence in mandatory competitions (Whyte et al, 2016). SCD is more common 
in males than females and most prevalent in U.S. athletes that were of African-American descent 
(Maron, Haas, Ahluwalia, Murphy, & Garberich, 2016). The highest incidence rate was in 
basketball, football, and track respectively (Whyte et al, 2016). SCA and SCD are actually seen 
at a higher frequency in the general population but because of the high health and fitness level of 
highly trained athletes, the occurrence of SCA and SCD is typically more unexpected and 
impactful.  
Prescreening Process 
In the United States, athletes at the high school and collegiate level are usually required to fill out 
a health history form and have a physical exam performed by a physician or athletic trainer yearly. 
Most professional sports teams also require a health history and physical exam that includes heart 
rate and blood pressure at the beginning of each season (Piper & Stainsby, 2013). Some teams 
include an electrocardiogram (Mosterd, 2018) in their pre-season physical but this is not common 
and not required (Riebe, Ehrman, Liguori & Magal, 2018; Piper & Stainsby, 2013). Pre-screening 
is the first line of defense in SCA and SCD stressing the importance of efficient and accurate 
testing.  
American Heart Association pre-participation screening protocol 
 
 
Table 2: 12-point Pre-Participation Screening for Athletes by AHA 
 
 
Pre-participation screenings became an initiative in 1996 and was supported by the American 
Heart Association (AHA), but there are no current regulated guidelines (Subasic, 2009). In a policy 
guidance released by the AHA, they revealed that only about 6% of doctors in Washington State 
followed the guidelines they set out (Preparticipation). There is a 12-point assessment that involves 
a physical examination and a health history that must be verified by a parent for minors (Subasic, 
2009). This 12-point assessment is shown in Table 2 from the American Heart Association  The 
health history questionnaire targets the possibility of heart-related abnormalities based on personal 
and familial history (Subasic, 2009). The questionnaire contains 5 questions pertaining to chest 
pain, syncope, excessive fatigue in the presence of exercise, heart murmur and elevated blood 
pressure that may or may not be present in the athlete (Subasic, 2009). Following this questionnaire 
are 3 questions pertaining to history of sudden death, heart disease before age 50, and any other 
cardiovascular condition that may be present in the patient’s family (Subasic, 2009). The four 
elements of the physical exam include physical appearance of Marfan syndrome, resting blood 
pressure from both arms while sitting, listening for presence of heart murmur, and palpation of the 
femoral pulse (Subasic, 2009). Those performing the physical, qualified practitioners, also listen 
for heart murmur when the patient moves from sitting to standing as well as while performing the 
Valsalva maneuver (Subasic, 2009). It is recommended that these pre-screenings take place 
annually and if any of the 12-points indicate a possible cardiac abnormality, the patient is 
recommended for further evaluation before being allowed to participate (Subasic, 2009). 
Professional sports in the United States, however, have adopted the European Society of 
Cardiology screening that includes a 12-lead ECG along with the health history and physical 
examination (Corrado, Basso, Schiavon, Pelliccia, &Thiene, 2008). 
European Society of Cardiology pre-participation protocol 
The European Society of Cardiology (ESC) has a similar protocol to the AHA when performing a 
pre-participation screening on athletes with one major difference; a 12-lead electrocardiogram 
(Mosterd, 2018).  
 
Figure 3: Sudden Cardiac Death in Young People and Athletes; flowchart of ESC pre-
participation screening protocol 
 
The overall pre-participation process is shown in Figure 3 from an article in the Italian Journal of 
Medicine (Corrado & Zorzi, 2018). Phase one of the screening is a family and personal health 
history, a physical examination, and a 12-lead ECG. If these all have negative findings, then the 
athlete is cleared for competition. If there are any concerns regarding one of these factors, the 
patient is referred for further examination that includes an echocardiogram, stress test, 24-hour 
Holter monitor, a magnetic resonance imaging (MRI) scan of the heart, and/or an angiography 
among any other test a cardiologist deems necessary (Corrado & Zorzi, 2018). If results come back 
negative, the athlete is free to participate, and if positive, the athlete starts treatment for underlying 
cardiovascular condition.  
 
Ethical and Legal Considerations for Pre-Participation Screenings 
For athletes that are associated with a school or college, the school system or NCAA is ethically 
responsible for producing a cost-effective and efficient pre-participation screening to maximize 
the safety of their athletes (Maron 2012). Although the ethical responsibility falls on the 
institutions where the athlete is participating at, there is no real legal responsibility on these places 
to provide an adequate screening (Maron 2012). This legal responsibility does not fall on the 
physician or any other medical professional that clears the athlete for participation in exercise 
either and to form a malpractice suit against the physician requires adequate proof which is hard 
to come by (Maron, 2012). Because there are no legal responsibilities to either the institution or 
medical professional, where does it fall? There aren’t mandates on reporting SCA and SCD in 
young athlete’s either, so how are athlete’s being protected in the case that a faulty pre-
participation screening doesn’t catch a cardiac abnormality resulting in the athlete’s death? 
ECG addition to the AHA model 
There is evidence that an ECG included in the pre-participation screening of young athletes can 
help identify cardiovascular conditions that a physical examination or health history can’t (Casa 
& Stearns, 2017). Because of costs and access, the AHA decided not to include ECG in the 
screening in 2007 (Subasic, 2009). Adding the ECG has been a topic of debate for years due to the 
possibility of false-positive results and lack of resources (Subasic, 2009). The concern in including 
ECG in the screening process revolves around the possibility of false-negative as well as false-
positive results. One study on the Italian model of screening found an overall 7% false positive 
rate and an overall 2% disqualification rate (Casa & Stearns, 2017). Because the number of 
individuals that participate in athletics in the Untied States is much greater than that of Italy and 
assuming the percentages stayed the same country to country, the amount of false-positives and 
therefore disqualification from sport would be undesirable (Casa & Stearns, 2017). But do the 
benefits outweigh the risks of not using ECG? One study showed that 95% of patients that suffered 
from SCD had conditions that could have been found using an ECG (Casa & Stearns, 2017).  A 
single ECG prior to the beginning of athletics in high school may be beneficial to the athlete’s 
career and more cost-efficient than a repeated scan every year. ECG can pick up a multitude of 
abnormalities including HCM which is the number one cause of SCD in athletes in the United 
States (Casa & Stearns, 2017).  HCM can present itself as early as early childhood and as late as 
mid adulthood and is often asymptomatic (Casa & Stearns, 2017). Because it can develop between 
any of these ages, a single ECG, while cost effective, may not be adequate to identify those 
individuals that have the genetic disorder. The main question to be asked, does the possibility of 
false-positives and false-negatives outweigh the cases that could be caught and prevented? 
Emergency response to SCA 
Because the pre-participation screening can’t predict when, where, and to whom a SCA will 
happen, emergency preparedness is extremely important. Emergency response, meaning cardio 
pulmonary resuscitation (CPR) and automated external defibrillator (AED) use, is considered 
secondary prevention methods for SCD (Casa & Stearns, 2017). For young athletes, this means 
quick and easy access to an AED, an athletic trainer on site, and an emergency preparedness plan 
in place are all vital to SCA outcome.  
AED access 
An AED should also always be available to coaches, athletes, athletic trainers, or anyone else 
that is present at an athletic event. The AED is crucial in the survival of individuals who suffer 
from SCA. Survival of a cardiac arrest increases from 9% with CPR only, to 38% with the use of 
CPR in conjunction with an AED (Piper & Stainsby, 2013). CPR and AED are considered 
secondary management for SCA cases and pre-participation screenings are considered the 
primary protection stressing the importance of an adequate screening protocol. Because VF 
occurs in 40% of SCA cases, and it is a shockable rhythm, AED access is essential to survival of 
these athletes (Casa & Stearns, 2017). While there are some mandates put on AED placement, 
not all individuals present at a practice or competition know where it is located. It should be a 
part of the first team meeting and should be clearly visible and accessible to anyone present. 
AED legislation differs state to state and in North Carolina there are currently no laws regarding 
AED maintenance or notification of use (North Carolina State AED law). 
CPR certified individuals 
Although it has been seen that AED use has a higher percentage of survival, CPR use is also 
important to save lives. CPR should be started immediately and used while the AED is being 
retrieved. For this reason, it is vital to have individuals that are CPR certified present at every 
team practice, conditioning day, and competition (Drezner et al, 2018).  
Mandatory Reporting 
There is no mandatory reporting in the case of a SCA or SCD (Casa & Stearns, 2017). While the 
occurrence does often catch the attention of the media, it can just as easily be swept under the 
rug. A mandatory reporting system would allow for easier collection on the data surrounding 
sudden cardiac events and give even further insight into the most common causes and further 
improvement to prevention measures.  
Case Studies 
When an athlete suffers from a sudden cardiac arrest and survives, it gives professionals an insight 
into what might be happening structurally, electrically, or otherwise. The following two case 
studies show how unpredictable SCAs can occur and how even advanced medical screenings may 
not help predict these occurrences. Omar Carter’s story was provided via personal interview and 
the case of the hockey player was a case study published in an academic journal. Both stories stress 
the importance of emergency preparedness and immediate response. 
Hockey player 
This case study comes from a 23-year-old hockey player that suffered an SCA while playing in a 
hockey game. There were no previous symptoms, the player had not recently taken any contact, 
and there was no history of trauma (Piper & Stainsby, 2013). It took EMS 12 minutes to get there 
from the start of CPR and other players used an AED to restart his heart (Piper & Stainsby, 2013). 
He was transported to the hospital and an initial ECG was taken (Piper & Stainsby, 2013). It 
showed a decrease in left ventricular function (Piper & Stainsby, 2013). The second ECG taken 
later showed no dysfunction but a dilated right ventricle attributed to his status of an athlete (Piper 
& Stainsby, 2013). He had multiple tests taken which showed normal coronary arteries, no 
evidence of a myocardial infarction, no HCM, no scarring, and no fibrosis so he was diagnosed 
with a SCA of idiopathic origin (Piper & Stainsby, 2013). He received an implantable cardioverter-
defibrillator (ICD) and still has not been cleared to return to play (Piper & Stainsby, 2013). All 
tests following discharge from the hospital came back with no abnormalities and the cause is still 
unknown (Piper & Stainsby, 2013). As a part of pre-participation screenings for his team, he had 
been given a yearly physical that included checking heart rate and blood pressure as well as an 
ECG prior to the SCA (Piper & Stainsby, 2013). There had been no abnormalities reported in these 
previous tests either (Piper & Stainsby, 2013).  A secondary method of prevention in this situation 
saved this individuals life, demonstrating the importance of the use of CPR and an EAD.  
Omar Carter 
Omar Carter was an athlete his whole life. He played a multitude of sports starting at a young age 
but it was pain in his arm while he was doing push-ups when he was 16 that initially brought him 
into the doctor. He described pain in his left arm during conditioning and was taken to the hospital 
as a precaution. An ECG and an echocardiogram were performed on him there and his heart was 
considered borderline for HCM. There was no family history of any heart condition and even his 
twin brother did not exhibit these same abnormalities. His first doctor made him stop all sports 
until there were more tests run and ultimately Carter changed doctors to complete these tests. His 
second diagnosis was an unknown arrhythmia. Following this diagnosis, Carter was permitted to 
rejoin his sports teams but had to have tests including ECG, echocardiogram, stress test, and 
wearing a portable heart monitor every 3 months for the next year. The next year the tests moved 
to every 6 months and after that the tests were performed annually. As he transitioned into 
collegiate athletics on the Appalachian State Men’s Basketball team, he continued these annual 
exams that aligned with a more extensive NCAA athletic physical. He was only allowed to play 
basketball and wasn’t allowed to perform any exercise that was considered too strenuous. He made 
it through college without any incidents and moved on to play professional basketball in the 
Dominican Republic. It was during warm-ups of one of his professional games that Carter 
collapsed on the court and his heart stopped for approximately 12 minutes. He credits a nurse in 
the crowd with saving his life due to her quick action of immediately starting CPR. He was revived 
with an AED and spent the next couple of months in the hospital. While there he was given 3 shots 
a day (one in the stomach and 2 in the arm) to treat a low potassium level. After his hospital stay, 
Carter’s diagnosis was changed to “undiagnosed high blood pressure” and this remains his current 
diagnosis. A portable defibrillator was the first treatment and then in 2013 he had an ICD placed. 
He still has memory loss surrounding his cardiac arrest and has not played basketball or any sport 
since. Exercise that is permitted for him are light biking or walking and he maintains a heart-
healthy and balanced diet. When asked what he would change about current pre-screening 
processes, he suggested adding testing such as an ECG and/or stress test to the mandatory pre-
participation guidelines. He also pushed for more extensive participation in programs like Heart 
of a Champion. Carter is an example of an athlete that had all the tests and saw the cardiologist 
regularly but still had a SCA. His story stresses the importance of immediate emergency 
preparedness and response. Carter has since started the Omar Carter Foundation where he teaches 
people bystander CPR (O. Carter, personal communication, February 23rd, 2019).  
Conclusion 
While it may be impossible to diagnose and prevent all cases of SCA and SCD in young athletes, 
including an ECG in the pre-participation screening can increase the current number of incidences. 
Mandates should also be implemented on mandatory reporting, emergency action, and AED 
placement.  
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